LY03020
Phase 2Small molecule
Luye Pharma Group Ltd.LY03020 is one of 34 small molecule programs targeting Schizophrenia. It is currently in Phase 2.
1
Indications
4
Total Trials
3
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Celexa
AbbViePreclinical
Resotran
TakedaPreclinical
Ozempic
Novo NordiskPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY03020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company